MHLW Approved GSK’s Lamictal And Pfizer’s Genotropin Among Other Drugs
This article was originally published in PharmAsia News
The first division on drugs of Ministry of Health, Labor and Welfare's Pharmaceutical Affairs and Food Sanitation Council approved July 25 GlaxoSmithKline's antiepileptic drug Lamictal (lamotrigine) to treat partial seizures in pediatric and adult patients with Lennox-Gastaut syndrome, Pfizer's human growth hormone Genotropin (somatropin), Novartis' Neoral (cyclosporine) to treat atopic dermatitis, Santan Pharmaceutical's tafluprost to treat galucoma and ocular hypertension, Aska Pharmaceutical's Menoaid Combipatch to treat menopausal symptoms and Schering-Plough's Bepricor (bepridil) to treat atrial fibrillation.(Click here for more - Japanese language) "First Section Of PAFSC Approves Epilepsy Drug Lamictal Among Other Drugs" - Yakuji News (7/29/08)
You may also be interested in...
Many materials subject to order, APIs needed for OTC as well as Rx drugs, are supplied by companies outside the US, and China accounts for the bulk of them. The order didn't specify countries and products, leaving decisions to FDA.
Order sets a path for federal government to use its power as a purchaser of pharmaceuticals to nurture a high-tech domestic pharma manufacturing sector that would increase resilience against threats that could isolate the US from countries like China that are important nodes in the global manufacturing supply chain.
Will the US FDA agree to more structured communications amid its struggles with the existing meeting workload?